Meeting
2023 ASCO Annual Meeting
Outcomes in premenopausal patients with HR+/HER2- breast cancer and lymph node micro-metastasis based on the 21-gene recurrence score.
Authors
Nadeem Bilani
Icahn School of Medicine at Mount Sinai Morningside-West, New York, NY
Nadeem Bilani , Rima Patel , Amy Tiersten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 571)
DOI
10.1200/JCO.2023.41.16_suppl.571
Abstract #
571
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Ovarian function suppression is not indispensable in patients with early breast cancer who are older than age 40.
First Author: Jianqiao Xian
Poster
2021 ASCO Annual Meeting
Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.
First Author: Matteo Lambertini
Poster
2020 ASCO Virtual Scientific Program
Real-world patterns of treatment and recurrence by frailty status among older women with HR-positive, HER2-negative early breast cancer.
First Author: Gregory Sampang Calip
Poster
2015 ASCO Annual Meeting
Impact on relapse free survival (RFS) of time to hormone therapy (HTx) after diagnosis (Dx) of low risk hormone receptor positive (HR+) early breast cancer (BC).
First Author: Wen Yee Chay